Abeona Therapeutics Inc. (NASDAQ:ABEO)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a research note issued on Wednesday. They presently have a $14.00 target price on the biopharmaceutical company’s stock. Maxim Group’s price target would suggest a potential upside of 112.44% from the company’s current price.

ABEO has been the topic of several other reports. FBR & Co reiterated a “buy” rating and issued a $15.00 price objective on shares of Abeona Therapeutics in a research report on Friday, August 26th. Rodman & Renshaw reiterated a “buy” rating and issued a $17.00 price objective on shares of Abeona Therapeutics in a research report on Sunday, August 21st. Cantor Fitzgerald initiated coverage on shares of Abeona Therapeutics in a research report on Wednesday, September 7th. They issued a “buy” rating and a $21.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Abeona Therapeutics in a research report on Thursday, October 6th. Finally, Zacks Investment Research upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, August 29th. One analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $14.50.

Analyst Recommendations for Abeona Therapeutics (NASDAQ:ABEO)

Abeona Therapeutics (NASDAQ:ABEO) traded down 0.91% during trading on Wednesday, hitting $6.53. 81,254 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $5.36 and its 200 day moving average price is $3.47. Abeona Therapeutics has a 12-month low of $2.05 and a 12-month high of $7.19. The stock’s market cap is $219.05 million.

Abeona Therapeutics (NASDAQ:ABEO) last posted its quarterly earnings results on Tuesday, August 16th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.14) by $0.06. Abeona Therapeutics had a negative net margin of 2,177.03% and a negative return on equity of 30.84%. Analysts anticipate that Abeona Therapeutics will post ($0.73) earnings per share for the current fiscal year.

In related news, Director Todd Wider purchased 5,000 shares of the company’s stock in a transaction on Tuesday, September 20th. The shares were bought at an average cost of $5.48 per share, for a total transaction of $27,400.00. Following the transaction, the director now owns 75,000 shares of the company’s stock, valued at $411,000. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 13.00% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ABEO. Geode Capital Management LLC increased its stake in Abeona Therapeutics by 16.7% in the first quarter. Geode Capital Management LLC now owns 70,496 shares of the biopharmaceutical company’s stock worth $180,000 after buying an additional 10,082 shares during the period. Sabby Management LLC increased its stake in Abeona Therapeutics by 11.4% in the first quarter. Sabby Management LLC now owns 334,108 shares of the biopharmaceutical company’s stock worth $855,000 after buying an additional 34,108 shares during the period. Finally, Royce & Associates LP increased its stake in Abeona Therapeutics by 25.6% in the first quarter. Royce & Associates LP now owns 376,321 shares of the biopharmaceutical company’s stock worth $963,000 after buying an additional 76,678 shares during the period. Institutional investors own 19.95% of the company’s stock.

About Abeona Therapeutics

Abeona Therapeutics, Inc (Abeona), formerly PlasmaTech Biopharmaceuticals, Inc, is focused on developing and delivering gene therapy and plasma-based products for rare diseases. The Company’s lead programs are ABO-101 (AA9 NAGLU) and ABO-102 (scAAV9 SGHG), adeno-associated virus (AAV)-based gene therapies for Sanfilippo syndrome (Mucopolysaccharidosis (MPS) IIIA and IIIB) in collaboration with patient advocate groups, researchers and clinicians.

5 Day Chart for NASDAQ:ABEO

Receive News & Stock Ratings for Abeona Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics Inc. and related stocks with our FREE daily email newsletter.